Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07276958
PHASE1

A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Participation in the study will last up to approximately 52 weeks.

Official title: A Phase 1, Multicenter, Randomized, Placebo-Controlled, Participant-Blind, Single-Ascending Dose Study of LY4298445 in Healthy Participants and an Open-Label Single-Ascending Dose and Multiple-Ascending Dose Study of LY4298445 in Participants With Systemic Lupus Erythematosus or Rheumatoid Arthritis

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

63

Start Date

2026-02-04

Completion Date

2028-03

Last Updated

2026-03-23

Healthy Volunteers

Yes

Interventions

DRUG

LY4298445

Administered SC

DRUG

LY4298445

Administered IV

Locations (7)

Nucleus Network

Brisbane, Australia

Nucleus Network

Melbourne, Australia

Peking University First Hospital

Beijing, China

Peking University Third Hospital

Beijing, China

Xiangya Hospital of Central South University

Changsha, China

Renji Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China

Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, China